tm logo

Monitor this mark

View On USPTO

NUPREVIQ
Live/Registered
SECTION 71 ACCEPTED

on 11 Jul 2022

Last Applicant/ Owned by

Octapharma AG

Seidenstrasse 2

Lachen

CH

8853

Serial Number

79169811 filed on 15th May 2015

Registration Number

4872533 registered on 22nd Dec 2015

in the Principal Register

Correspondent Address

Henry B. Ward, III

Henry B. Ward, III Bradley Arant Boult Cummings LLP

Charlotte, NC 28202

United States

Filing Basis

1. filing basis filed as 66 a

Disclaimer

NO DATA

NUPREVIQ

Medical testing of patients for determining individual risk of forming inhibitors during a hemophilia treatment with factor VIII

Classification Information

Class [044]
Medical, Beauty & Agricultural Services

Medical testing of patients for determining individual risk of forming inhibitors during a hemophilia treatment with factor VIII

First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details

Serial Number

No 79169811

Mark Type

No Service Mark

Attorney Docket Number

No 302058401185

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

Yes

66A Current

Yes

Current Basis

No

No Basis

No

Legal History

Show more

Status DateAction Taken
05th Jun 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
05th Jun 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05th Jun 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11th Jul 2022REGISTERED-SEC.71 ACCEPTED
11th Jul 2022NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
06th Jun 2022CASE ASSIGNED TO POST REGISTRATION PARALEGAL
21st Dec 2021TEAS SECTION 71 RECEIVED
19th Aug 2016NOTIFICATION PROCESSED BY IB
18th Aug 2016NEW REPRESENTATIVE AT IB RECEIVED
11th Aug 2016NEW REPRESENTATIVE AT IB RECEIVED